Stifel upgrades Vor Biopharma stock to Buy on telitacicept prospects
PositiveFinancial Markets

Stifel has upgraded Vor Biopharma's stock to a 'Buy' rating, highlighting the promising prospects of telitacicept, a drug that could significantly impact treatment options in its field. This upgrade reflects confidence in the company's potential to deliver innovative therapies, which is crucial for investors looking for growth in the biopharma sector.
— Curated by the World Pulse Now AI Editorial System